

Deubiquitinating Enzyme Usp12 Is a Novel Co-activator of the Androgen Receptor*

Received for publication, May 15, 2013, and in revised form, September 16, 2013. Published, JBC Papers in Press, September 21, 2013, DOI 10.1074/jbc.M113.485912

Urszula L. Burska¹, Victoria J. Harle¹, Kelly Coffey, Steven Darby, Hollie Ramsey, Daniel O'Neill, Ian R. Logan, Luke Gaughan, and Craig N. Robson²

From the Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom

Background: Androgen receptor (AR) is the principle therapeutic target in prostate cancer.

Result: We have established that Usp12 deubiquitinates and stabilizes the AR resulting in increased transcriptional and pro-proliferative activity.

Conclusion: We have identified Usp12 to be a novel positive regulator of AR.

Significance: Usp12 presents a therapeutic target upstream of AR that could enable bypassing the limitations of therapeutics aimed specifically at AR.

The androgen receptor (AR), a member of the nuclear receptor family, is a transcription factor involved in prostate cell growth, homeostasis, and transformation. AR is a key protein in growth and development of both normal and malignant prostate, making it a common therapeutic target in prostate cancer. AR is regulated by an interplay of multiple post-translational modifications including ubiquitination. We and others have shown that the AR is ubiquitinated by a number of E3 ubiquitin ligases, including MDM2, CHIP, and NEDD4, which can result in its proteosomal degradation or enhanced transcriptional activity. As ubiquitination of AR causes a change in AR activity or stability and impacts both survival and growth of prostate cancer cells, deubiquitination of these sites has an equally important role. Hence, deubiquitinating enzymes could offer novel therapeutic targets. We performed an siRNA screen to identify deubiquitinating enzymes that regulate AR; in that screen ubiquitin-specific protease 12 (Usp12) was identified as a novel positive regulator of AR. Usp12 is a poorly characterized protein with few known functions and requires the interaction with two cofactors, Uaf-1 and WDR20, for its enzymatic activity. In this report we demonstrate that Usp12, in complex with Uaf-1 and WDR20, deubiquitinates the AR to enhance receptor stability and transcriptional activity. Our data show that Usp12 acts in a pro-proliferative manner by stabilizing AR and enhancing its cellular function.

The androgen receptor (AR)³ belongs to the nuclear hormone receptor superfamily and plays a key role in the transcriptional regulation of numerous genes important in the develop-

ment of both normal and malignant prostate (1). Ligand binding of the AR in the cytoplasm results in dimerization, translocation to the nucleus, and transcription of androgen-responsive genes. Deregulation of AR signaling leads to the development of prostate cancer (PCa), and as such the receptor represents the most common therapeutic target in PCa (1). The current clinical strategies in PCa revolve around anti-hormone therapies and aim to pharmacologically decrease serum androgen levels. This is currently achieved through the use of luteinizing hormone-releasing hormone agonists such as goserelin or anti-androgens which can be either steroidal (cyproterone acetate) or nonsteroidal (flutamide) and function by competitively inhibiting the AR (2). However, despite initial success most of anti-androgen therapies will invariably fail resulting in castrate-resistant prostate cancer (CRPCa). Importantly, the AR signaling cascade remains functional in CRPCa. Treatment failure can be caused by changes in AR signaling, including alterations in AR cofactor levels and activity as well as emergence of AR mutations that permit receptor activity in the presence of non-androgenic steroids and anti-androgens (2). In CRPCa, AR still remains a crucial target, with increased AR levels and gene amplification observed in 30% of patients. Increased levels of the downstream gene prostate-specific antigen (PSA) in the serum are also associated with PCa recurrence (3). Previous research demonstrated that even at CRPCa stage, depletion of AR by siRNA treatment decreased tumor growth. Similarly, AR overexpression in PCa xenograft in castrate animals still enhanced cancer growth (4).

AR function and activity are known to be regulated by a number of post-translational modifications. In response to androgens, AR is phosphorylated by kinases including AKT (5) and TFIH (6), resulting in changes to transcriptional activity and cellular localization. This can be reversed by phosphatases such as protein phosphatases 1 and 2A (7). Acetylation by p300 (8) and Tip60 (9) enhances transcriptional activity which can be reversed by the histone deacetylases HDAC1 (10) and SIRT1 (11). AR is also subjected to SUMOylation by PIAS1 and PIASx α , a process that is believed to decrease its transcriptional activity (12). We and others have shown that the AR is also

* This work was supported by Prostate Cancer United Kingdom, Cancer Research UK, and the Medical Research Council.

¹ Both authors contributed equally to this work.

² To whom correspondence should be addressed. Tel.: 44-191-246-4426; Fax: 44-191-246-4301; E-mail: c.n.robson@ncl.ac.uk.

³ The abbreviations used are: AR, androgen receptor; ARE, androgen-responsive element; CRPCa, castrate-resistant prostate cancer; DHT, dihydrotestosterone; IP, immunoprecipitation; PCa, prostate cancer; PI, propidium iodide; PSA, prostate-specific antigen; qPCR, quantitative PCR; SCR, scrambled; Usp, ubiquitin-specific protease.

Usp12 Is a Novel Positive Regulator of the AR

ubiquitinated by a number of E3 ubiquitin ligases, including MDM2 (13, 14), CHIP (15, 16), and NEDD4 (17, 18) which results in proteosomal degradation. AR ubiquitination can also lead to the increase in transcriptional activity; RNF6 has been reported to ubiquitinate AR at Lys-845 and Lys-847, promoting its activity by allowing ARA54 co-activator recruitment (19). Further details of AR post-translational modifications have been recently reviewed (20).

Ubiquitination of AR causes a change in AR activity and stability and impacts both survival and growth of PCa cells. As a result deubiquitination of those sites has an equally important role.

Currently, very little is known about the enzymes that deubiquitinate AR. It has been reported that Usp26 can directly bind and deubiquitinate AR, acting as a co-regulator of AR by reversing AR activation and degradation by MDM2 ubiquitination depending on cellular context (21). Additionally, Usp10 has been reported to bind AR, resulting in increased transcriptional activity (22).

In this study we focused on Usp12, a deubiquitinating enzyme identified in an siRNA screen as a positive regulator of AR. Usp12 has three reported targets; histones H2B, H2A (23), and nonactivated Notch (24). Usp12 is highly homologous to Usp46 and Usp1, and its activity, similar to that of Usp46, is enhanced by binding to its cofactors Uaf-1 and WDR20, with Uaf-1 required for enzymatic activity of Usp12 (25–27). It has been reported that Uaf-1 binds and stabilizes Usp12, and this complex is bound by WDR20. This interaction is both stoichiometric and evolutionarily conserved and has been shown to play the same role in *Schizosaccharomyces pombe* (28). Usp12 and Uaf-1-containing complex was shown to deubiquitinate all types of ubiquitin chains apart from linear chains (27). Our search of Oncomine profiles revealed that Usp12 is differentially expressed in bladder, brain, CNS, cervical, kidney, lymphoma, and ovarian cancer samples compared with healthy controls.

We now show that Usp12, in complex with Uaf-1 and WDR20, interacts with and deubiquitinates the AR resulting in increased protein stability and transcriptional activity. Moreover, we report that Usp12 depletion reduces PCa cell proliferation and up-regulates cell apoptosis, suggesting that it is an additional regulator of the AR that may represent a novel target for therapy.

EXPERIMENTAL PROCEDURES

Antibodies and Plasmids—Antibodies used were anti-FLAG (Sigma), anti-Usp12 (Dundee Cell Products), anti-AR (Santa Cruz Biotechnology; N20 clone), anti-HA (Santa Cruz Biotechnology; Y11 clone), anti- α -tubulin (Sigma), and anti-ubiquitin (Santa Cruz Biotechnology). Plasmids used were pPSA-Luc, pARE3-Luc, pCMV- β -gal, pFLAG-His-AR (9), pFLAG-Usp12 wild type, and C48A mutant generated by *in vitro* mutagenesis (QuikChange; Stratagene), pHA-ubiquitin and pHA-FLAG-WDR20 and pFLAG-Uaf-1 (25, 26), which were kind gifts from Professor Alan D'Andrea (Dana-Farber Cancer Institute, Boston).

Cell Culture, Transfections, and Reporter Assays—LNCaP, HEK293T, and COS-7 cells were obtained from American Type Culture Collection (Manassas, VA). VCaP cells were kindly

donated by Professor Guido Jenster (Erasmus Medical Centre, Rotterdam). Cells were cultured in RPMI 1640 medium with 2 mM L-glutamine (Invitrogen) supplemented with 10% (v/v) fetal calf serum (FCS) at 37 °C in 5% CO₂. LNCaP-AI variant cell line was derived in-house by culturing LNCaP cells in steroid-depleted medium (DCC) to allow for the development of androgen independence (30). LNCaP-7B7 cells stably overexpressing pPSA-Luc vector were kindly donated by Professor Jan Trapman (Erasmus Medical Centre) and cultured with the addition of 25 μ g/ml zeocin. Transfections were performed using TransIT-LT1 reagent (MirusBiol) following the manufacturer's instructions.

For luciferase assays, cells were transfected with 50 ng of pARE3-luc, 50 ng of pCMV- β -gal, and 10 ng of pFLAG-His-AR, pFLAG-Usp12, and pFLAG-Uaf-1 as required. All reactions were balanced with pCMV empty vector. Cells were cultured under steroid-depleted conditions for 48 h followed by supplementation with dihydrotestosterone (DHT), at a range of concentration of 5 and 10 nM with comparable results obtained for both concentrations, for an additional 24 h. Cells were lysed and incubated in 1 \times Promega luciferase assay reagents according to the manufacturer's instruction, and luciferase counts/s were established and normalized to β -galactosidase activity. Results were normalized to AR expression alone in steroid-depleted conditions.

siRNA Gene Silencing and Gene Expression Analysis—The generation and DUB siRNA screening methodology for AR regulators screen using an ELISA against PSA protein as a readout of AR activity in LNCaP cells have been described previously (29). Usp12 targeting siRNA sequences were: (A) GAAACUCUGUGCAGUGAAU[dTdT], (B) CAGAUCUCUCCAUAGCAU[dTdT], and (C) CAUCAGAUUUCUCAAAGAA[dTdT]; WDR20 was silenced with siRNAs (A) CGAGAAAGAUACAAAGCGA[dTdT] and (B) GUUUGACCCUUAUACCACU[dTdT] and Uaf-1 with (A) CAAAUUGGUUCUCAGUAGA[dTdT] and (B) CAUUGACUGCCUCAAUAA[dTdT]. Initial DUB screen used a pool of siRNAs against Usp12, and further experiments were performed using siRNA (B). Uaf-1 A achieved 61.5% knockdown with Uaf-1 B 61% similarly, WDR20 A achieved 67.4% and WDR20 B 57.4% in quantitative PCR (qPCR) validation (data not shown). As a result siRNAs (A) were selected for silencing of both Uaf-1 and WDR20.

LNCaP cells were reverse transfected with siRNA using RNAiMax (Invitrogen) according to the manufacturer's instructions and incubated in culture medium for 96 h prior to cell lysis and analysis by Western blotting as described previously (31) or qPCR. For qPCR RNA was extracted using the EZ RNA isolation kit (Biological Industries), and cDNA synthesis and data analysis were performed as described previously (32). Proliferation was measured by cell counting 96 h after gene silencing. To measure colony-forming ability cells were reverse transfected with siRNA for 72 h, followed by reseeding at varying cell densities and incubated for 14 days to allow colony formation and stained with crystal violet. Colonies were counted and the surviving fraction calculated (31).

Flow Cytometry—Cell cycle profiles were generated by propidium iodide (PI) staining, cells were permeabilized with 1% Triton X-100 and incubated with 1 μ g/ml RNaseA and PI fol-

lowed by analysis on FACScan (BD Biosciences) (33). Levels of apoptosis were analyzed after 96 h of gene silencing by annexin V assay (BD Biosciences) according to the manufacturer's instructions and analyzed on a FACScan. Cells were stained for both annexin V and PI positivity and during analysis divided into quarters representing normal cells, necrotic cells, and apoptotic cells.

Immunoprecipitations (IPs)—Cells were seeded at 5×10^5 cells/90-mm dish, transfected 24 h later with 1 μ g of each plasmid as indicated, incubated for 48 h, and lysed directly into lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.2 mM Na_3VO_4 , 1% Nonidet P-40, 1 mM PMSF, 1 mM DTT, and 1 \times protease inhibitors (Roche Applied Science)). Lysates were incubated with 1 μ g of antibodies as indicated for 16 h at 4 °, and antibodies were pulled down using protein G-Sepharose beads. For denaturing IPs, cells were subject to 20 μ M MG132 proteasomal inhibitor treatment for the final 16 h followed by collection into lysis buffer with an addition of 2% SDS and denatured at 100 °C for 10 min (29). After denaturation samples were diluted 10 \times in lysis buffer without SDS and processed as in native IP. Immunoprecipitants were analyzed using Western blotting.

Chromatin immunoprecipitations (ChIPs) were performed as described previously (10). LNCaP cells were transfected in steroid-depleted medium for 72 h followed by DHT treatment for 120 min. Data are presented as percentage input using the following formula: % input = $100 \times 2^*$ (CT adjusted input sample – CT immunoprecipitated sample). CT refers to cycle threshold.

Immunohistochemistry—Tissue microarray containing 0.6-mm cores of benign prostatic hyperplasia ($n = 7$), PCa ($n = 7$), and control tissues including breast, kidney, placenta, ovary, and liver was used. Antigens were retrieved by pressure cooking the tissue microarray in 0.01 M citrate buffer, pH 6.0, followed by staining the tissues with rabbit polyclonal anti-Usp12 antibody (Dundee Cell Products) (29).


RESULTS

Identification of Usp12 as a Positive Regulator of AR—To identify DUBs that regulate AR we conducted an siRNA screen in LNCaP cells using an ELISA detecting the levels of PSA, which is an AR target gene product, and as such its levels will be affected by any change in AR activity, as a surrogate readout of AR activity. All samples were normalized against the scrambled control (SCR), and readouts of ± 2 -fold PSA protein level compared with SCR were taken for further validation. To confirm that target DUBs regulate AR transcriptional activity and not only PSA secretion, further validation included the assessment of PSA mRNA levels upon DUB depletion, eliminating DUBs that solely affect PSA rather than AR activity. Of the 78 screened DUBs, four were identified as potentially involved in androgen-dependent regulation of AR. Silencing of one of the targets, Usp12, resulted in 73% reduction in PSA protein levels (Fig. 1A, *highlighted panel*). This result was also confirmed by Western blotting (Fig. 1B). Usp12 siRNA was shown to significantly decrease Usp12 transcript levels in three PCa cell lines, namely, LNCaP, LNCaP-AI, and VCaP (Fig. 1C). Additionally, depletion of Usp12 resulted in significant decrease of PSA transcript in LNCaP, LNCaP-AI, and VCaP cells, confirming that

Usp12 affects AR transcriptional activity and as a result PSA gene expression rather than protein secretion (Fig. 1C). To summarize, Usp12 has been identified as a positive regulator of AR in multiple PCa cell lines, and it was selected for further validation and analysis.

Usp12 Stabilizes AR at the Protein Level—Ubiquitination of AR causes a change in AR activity and stability and impacts both survival and growth of PCa cells, as a result deubiquitination of those sites has an equally important role. We hypothesized that Usp12 affects AR activity by deubiquitinating it and as a result stabilizing AR protein. To determine the effects of Usp12 on AR activity and protein stability we analyzed the levels of endogenous AR in PCa cells depleted of Usp12. Silencing of Usp12 resulted in a decrease of AR protein compared with SCR in three PCa cell lines (Fig. 2, A–C). Stabilization of AR by Usp12 relies on enzymatic activity of this DUB as mutant Usp12_{C48A} was not able to stabilize AR protein levels to the same extent as the wild type (Fig. 2D). Additionally as little as 1:10 of Usp12 (50 ng) to AR (500 ng) was sufficient to cause this effect (Fig. 2D). Similarly, when HEK293T cells were transfected with AR and co-transfected with Usp12, Uaf-1, and WDR20 the levels of AR increased compared with AR alone (Fig. 2E). Even the increase in AR protein levels observed in cells transfected with Uaf-1 and WDR20 can be attributed to the stabilization of endogenous Usp12 caused by the overexpression of its cofactors as illustrated by Usp12 protein levels (Fig. 2E). To assess whether reduced receptor levels were a consequence of compromised AR gene expression we analyzed AR transcript level in LNCaP cells depleted of Usp12. Knockdown of Usp12 or either one of its interacting partners had no statistically significant effect on AR transcript levels suggesting that Usp12 may function to enhance the stability of the AR in PCa cells (data not shown). Additionally, we investigated the effects of Usp12 depletion on AR half-life in PCa cells. In cells with depleted Usp12 the pool of AR was smaller than in controls even before the cycloheximide treatment and there was a trend of decreased half-life of AR (Fig. 2F). In conclusion we have shown that Usp12, with its interacting partners Uaf-1 and WDR20, increases AR protein levels rather than regulating its gene expression.

AR Stabilization by Usp12 Results in Increased AR Activity—To assess the effects of increased AR protein stability HEK293T cells were transfected with an androgen-responsive luciferase reporter containing three adjacent androgen-responsive elements (AREs) upstream from the *luciferase* gene. Additionally, combinations of mammalian expression vectors including dual FLAG-AR, FLAG-Usp12, and FLAG-Uaf-1 were co-transfected, and receptor activity was assessed. Cells transfected with Usp12 showed a trend of increased AR transcriptional activity which was not statistically significant (Fig. 3A); however, when Usp12 and Uaf-1 were co-transfected, AR transcriptional activity was significantly increased to levels comparable with that caused by the known AR co-regulator p300 (Fig. 3A). This result is in agreement with previous reports that Usp12 requires the presence of Uaf-1 for its enzymatic activity (27). To confirm a transcriptional co-regulatory role of Usp12 in the AR signaling cascade, we assessed AR activity upon depletion of Usp12 in the LNCaP variant cell line, LNCaP-7B7, which have a






FIGURE 2. Usp12 stabilizes AR at the protein level. A–C, LNCaP, LNCaP-AI, and VCaP cells, respectively, were treated with siRNA as indicated. LNCaP and VCaP cells were cultured in full media and LNCaP-AI in DCC. At 96 h cells were lysed followed by immunoblotting. D, COS-7 cells were transfected with 500 ng of pFLAG-His-AR and increasing amounts (10–500 ng) of wild type and C48A mutant Usp12 for 48 h. Reactions were balanced with empty pCMV vector. E, HEK293T cells were transfected with pFLAG-His-AR, pFLAG-Usp12, pFLAG-Uaf-1, and pHA-FLAG-WDR20 plasmids as indicated, and at 48 h cells were lysed followed by Western blotting. F, LNCaP cells were treated with siRNA as indicated for 96 h followed by treatment with 1 μ M cycloheximide for 0–4 h.

stably integrated *luciferase* gene under the control of the *PSA* promoter. Usp12 silencing caused a significant decrease in AR transcriptional activity both in steroid-depleted conditions and after DHT stimulation (Fig. 3B). Additional confirmation of Usp12 effects on AR transcriptional activity came from qPCR analysis, where we observed that Usp12 silencing caused a significant decrease of transcript levels of AR-regulated genes *PSA* and *TMPRSS2* (Figs. 3C and 1C) in multiple PCa cell lines. Further analysis of Usp12 silencing in LNCaP cells cultured in steroid-depleted conditions followed by DHT stimulation for 0–48 h showed a significant decrease in transcript levels of all five androgen-regulated genes that were tested (Fig. 3D). Our results confirm that the stabilization of AR caused by Usp12 results in enhanced transcriptional activity of AR and increased transcript levels of AR-regulated genes. To determine the underlying cause of the decreased transcriptional activity of AR we performed ChIP analysis of AR recruitment to AREIII of *PSA* enhancer after DHT stimulation. AR recruitment was shown to be significantly decreased after Usp12 silencing compared with SCR-treated control, further confirming the role of Usp12 in the regulation of AR activity (Fig. 3E).

Stabilization of AR by Usp12 Affects Survival and Proliferation of Prostate Cells—We have shown that Usp12 enhances AR activity by up-regulating receptor stability. We next assessed the role of Usp12 in regulating the survival and proliferation of PCa cell lines. Proliferation of three PCa cell lines was quanti-

fied by cell counting 96 h after Usp12 depletion. It was observed that Usp12 silencing caused a significant decrease in cellular proliferation in all three cell lines (Fig. 4A). To examine the impact of Usp12 knockdown on LNCaP cell survival, we measured apoptosis by annexin V staining by flow cytometry. Silencing of the Usp12 complex and Usp12 alone resulted in a significant increase of apoptotic cells that was comparable with the value obtained for cells with depleted AR (Fig. 4B).

Cell cycle analysis by PI staining revealed that depletion of the Usp12 complex results in a significant increase of G₁-arrested PCa cells (Fig. 4C). Additionally, silencing of the Usp12 complex significantly increased the number of cells in sub-G₁ phase, confirming that it causes an increase in cellular apoptosis (Fig. 4D).

One of the crucial properties of cancer cells is their ability to form colonies which allows for cancer survival. We evaluated the ability of LNCaP cells to form colonies after depletion of Usp12. Cells with silenced Usp12 had a significantly decreased ability to form colonies compared with SCR-treated control (Fig. 4E). In conclusion, we have shown that AR stabilization by Usp12 has a significant effect on proliferation and survival of PCa cells. Usp12 is pro-proliferative, and cells deficient in it have decreased ability to proliferate, have increased apoptosis and G₁ arrest, and are deficient in their ability to form colonies. These data suggest that Usp12 has a key role in PCa disease progression.

Usp12 Interacts with AR and Stabilizes It via Deubiquitination—We have shown that Usp12 stabilizes AR at the protein level and as a result increases transcriptional activity acting in a pro-survival manner in prostate cells. To determine whether Usp12 interacts with AR we immunoprecipitated AR and its interacting partners from the whole cell lysate. These immunoprecipitants were immunoblotted for the presence of Usp12. Both wild type Usp12 and its Cys-48 catalytically deficient mutant Usp12_{C48A} were shown to interact directly with AR (Fig. 5A). Additionally, we confirmed the interaction between the endogenous AR and Usp12 proteins in LNCaP PCa cells (Fig. 5B). To determine whether this interaction affects the AR ubiquitination status we transfected COS-7 cells with ubiquitin, AR, and wild type and the deubiquitinase-dead C48A mutant Usp12. Cells were treated with proteasomal inhibitors and lysed under denaturing conditions which ensures that only covalent bonds will remain unaffected, and as a result only direct ubiquitination of the AR rather than its interacting partners can be visualized. Lysates were subsequently immunoprecipitated using an anti-ubiquitin antibody which allowed separation of all directly ubiquitinated proteins and the levels of ubiquitinated AR visualized by immunoblotting the precipitant for AR protein. Wild type but not Cys-48-deficient mutant of Usp12 caused deubiquitination of AR (Fig. 5C).

To assess potential co-localization of the AR and Usp12 both proteins were ectopically expressed in COS-7 cells. Immuno-

FIGURE 1. Usp12 is a co-regulator of AR as shown by an siRNA screen. A, results of the siRNA screen show the effects of DUB knockdown on AR activity presented as a readout of PSA protein levels measured by an ELISA in LNCaP cells. B, LNCaP cells were treated with siRNA as indicated for 48 h prior to DHT stimulation for 0–72 h as indicated followed by lysis and immunoblotting. C, LNCaP, LNCaP-AI, and VCaP cells were treated with siRNA as indicated for 96 h. Total RNA was extracted, and qRT-PCR was performed to analyze the transcript levels of *Usp12* and *PSA* normalized to *HPRT1*. Data are presented as mean \pm S.E. (error bars) of three independent experiments normalized to scrambled (SCR). Statistical significance was analyzed using a *t* test.




FIGURE 3. Stabilization of AR by Usp12 results in increased transcriptional activity of AR. A, HEK293T cells were transfected with pARE3-luc, pCMV- β -gal, pFLAG-AR, pFLAG-Usp12, and pFLAG-Uaf-1 as indicated and cultured for 48 h in steroid-depleted conditions followed by addition of DHT for 24 h. Results are represented as a luciferase count/s normalized to β -galactosidase activity. Data are mean \pm S.E. (error bars) of three independent experiments normalized to AR alone. Statistical significance was analyzed with a *t* test. B, LNCaP-7B7 cells were incubated in steroid-depleted medium followed by gene silencing after 24 h. At 48 h DHT was applied and luciferase quantity determined 48 h later. Data were normalized to total protein content determined using a BCA assay. Data are displayed as the fold change in normalized luciferase activity compared with nontransfected cells without DHT treatment. Error bars represent S.E. of three independent experiments. C, LNCaP, LNCaP-AI, and VCaP cells were treated with siRNA as indicated for 96 h, total RNA was extracted, and quantitative RT-PCR was performed to analyze the transcript levels normalized to *HPRT1*. Data are a mean \pm S.E. of three independent experiments normalized to SCR. Statistical significance was analyzed with a *t* test. D, LNCaP cells were treated with siRNA for 48 h followed by stimulation with DHT for 0–48 h. Total RNA was extracted and quantitative RT-PCR performed to analyze the transcript levels normalized to *HPRT1*. Data are a mean \pm S.E. of three independent experiments normalized to SCR. Statistical significance was analyzed using a *t* test. E, LNCaP cells were treated with siRNA for 72 h in steroid-depleted medium. DHT was applied for 2 h before cells were harvested, and ChIP for AR recruitment to AREIII of PSA enhancer or control IgG was performed. Data are represented as percentage recruitment relative to input and are the mean of three independent experiments \pm S.E.

fluorescence and confocal microscopy were employed to visualize their cellular localization. It was observed that Usp12 and AR co-localize in the cytoplasm in steroid-depleted conditions (Fig. 5D). We have shown that enhanced levels of Usp12 result in increased AR protein stability and transcriptional activity. To confirm whether this increase in Usp12 can be observed *in vivo* we analyzed Usp12 positivity in benign and PCa patient samples. Usp12 protein levels were increased in PCa samples compared with benign controls (Fig. 5E). To summarize, AR and Usp12 interact, and enzymatically functional Cys-48 of Usp12 is not required for this interaction. Usp12 deubiquitinates AR through this interaction and for this intact Cys-48 of Usp12 is

required, as a result AR is stabilized at the protein level and its transcriptional activity is enhanced resulting in the activation of pro-survival pathways in prostate cells.

DISCUSSION

It is widely accepted that the post-translational regulation of AR protein stability is a crucial mechanism that regulates both normal and malignant prostate cells. Even in CRPCa AR still plays a major role and remains the main focus of therapeutic strategies, highlighting its importance as a drug target. Therapies aimed at AR invariably fail as a result of AR becoming promiscuous through mutations and acquiring the ability to become acti-




FIGURE 4. Stabilization of AR by Usp12 affects prostate cancer cell survival and proliferation. A, LNCaP, LNCaP-AI, and VCaP cells were treated with siRNA as indicated for 96 h, then silencing cellular proliferation was assessed by cell counting and normalized to SCR. Data are a mean \pm S.E. (error bars) of three independent experiments. Statistical analysis was undertaken with a *t* test. ***, $p < 0.001$; *, $p < 0.05$. B, LNCaP cells were treated with siRNA as indicated for 96 h, then silencing levels of apoptotic cells were determined by flow cytometry detection of annexin V-positive cells, and the results were normalized to SCR. Data are mean \pm S.E. of four independent experiments. Statistical determination was undertaken with an analysis of variance. C, LNCaP cells were treated with siRNA as indicated for 96 h, following silencing cell cycle status was determined by flow cytometry analysis of PI staining. Ratio of cells in G₁ versus S phase was determined, and results were normalized to SCR. Data are a mean \pm S.E. of three independent experiments. Statistical determination was undertaken with an analysis of variance. D, LNCaP cells were treated with siRNA as indicated for 96 h, following silencing the number of cells in sub-G₁ phase was determined by flow cytometry analysis of PI staining. Results were normalized to SCR. Data are a mean \pm S.E. of three independent experiments. Statistical determination was undertaken with analysis of variance. E, LNCaP cells were treated with siRNA as indicated for 72 h, following silencing cells were seeded at equal numbers with varied densities in 6-well plates and incubated for 14 days. At day 14 cells were fixed and stained with crystal violet, and the number of colonies in each sample was determined and normalized to SCR. Data are a mean \pm S.E. of three independent experiments. Statistical analysis was undertaken with a *t* test. Images show growth 14 days after seeding 4000 cells/2-mm well.

vated by a variety of steroid-based ligands as well as anti-androgens (2). As a result, more focus is needed on upstream co-regulators of AR as they could be potential drug targets.

Our study identified Usp12 as a novel positive regulator of AR through an siRNA screen of DUBs. Usp12 was initially identified as a histone H2B and H2A deubiquitinase (25, 23); recently, it was also reported to be a negative regulator of Notch signaling by impairing Notch trafficking and decreasing its cell surface levels (24). Still little is known about the role of Usp12 in humans, but the role of the Usp12 homologue in yeast has been researched in more detail with the enzyme shown to be involved in actin dynamics, cell polarity, and endocytosis (28). In *S. pombe*, silencing of the Usp12 homologue in combination

with Myosin-1 or Wiskott-Aldrich Syndrome protein (WAS) was reported to be lethal. Our data also point to the importance of Usp12 in cell survival as Usp12 depletion significantly increased the percentage of apoptotic cells and caused G₁ arrest in PCa cells, suggesting an evolutionarily conserved role of Usp12 in cell survival.

Usp12 DUB activity was previously shown to be very low in the absence of its binding partners, WD40 proteins Uaf-1 and WDR20 (27). Our reporter gene assays confirm this role of Uaf-1, and we have shown that without Uaf-1, Usp12 was not able to increase AR transcriptional activity whereas Usp12 knockdown alone was sufficient to decrease it. This confirms the role that Uaf-1 plays in regulating the activity of Usp12. In *S.*

Usp12 Is a Novel Positive Regulator of the AR




FIGURE 5. Usp12 interacts with AR resulting in AR deubiquitination and AR stabilization. *A*, HEK293T cells were transfected with plasmids as indicated, wild type (Usp12) and Cys-48-deficient mutant (Usp12M) of Usp12 were used. 48 h after transfection cells were harvested and lysates were immunoprecipitated (IP) with 1 μ g of AR antibody followed by immunoblotting. *B*, LNCaP cells were harvested, and lysates were immunoprecipitated for AR and with a nonspecific IgG. *C*, COS-7 cells were transfected with plasmids as indicated, and wild type (Usp12) and Cys-48-deficient mutant (Usp12M) of Usp12 were used. 72 h after transfection cells were treated with MG132 and harvested 16 h later. Lysates were denatured and subsequently immunoprecipitated with 1 μ g of ubiquitin antibody followed by immunoblotting. *D*, COS-7 cells were grown in steroid-depleted medium and transfected with equal amounts of Usp12-FLAG and AR plasmids. 48 h after transfection cells were fixed, and immunofluorescence followed by confocal microscopy were used to visualize the cellular localization of both proteins. DAPI was used as a nuclear stain. Scale bars, 20 μ m. *E*, Usp12 immunohistochemistry of PCa and benign patient samples are shown. Images are representatives of $n = 7$ for each group. Scale bar, 50 μ m.

pombe, binding partners were shown to be necessary not only for DUB activity but also to affect cellular localization of Usp12. Uaf-1 deletion traps Usp12 in the nucleus, and analogously WDR20 deletion traps Usp12 in the cytoplasm (28). It remains

to be established whether their role in Usp12 localization is conserved in human.

DUBs have been previously shown to affect AR stability. Usp10 is reported to bind to AR and positively regulate its tran-

scriptional activity (22). Recently, Usp10 effects on AR were proposed to be indirect via Usp10-mediated deubiquitination of H2A.Z leading to transcriptional activation of AR (35). This hypothesis requires further investigation in the context of Usp12 as it was also shown to deubiquitinate histones H2A and H2B (23). It is possible that the Usp12 effect on AR could be a combination of both direct deubiquitination and stabilization of the receptor and indirect regulation through deubiquitination of histones which allows transcriptional activation. Similarly, Usp26 is reported to assemble with AR and additional cofactors in subnuclear foci resulting in AR deubiquitination (21). We have also observed that Usp12 and AR co-localize and interact, resulting in deubiquitination of AR. Co-localization of AR and Usp12 occurs in the cytoplasm which can be explained by the large portion of the proteasome being present in the cytoplasm; it is also possible that for their co-localization in the nucleus additional Usp12 cofactors would need to be co-transfected to facilitate its shuttling similarly to what was observed in *S. pombe*. This causes stabilization of AR at a protein level. It has been previously published that silencing of AR results in G₁ arrest and increased apoptosis; interestingly, we have observed that Usp12 silencing has the same effects on PCa cells. These cellular effects might be mediated by a combination of both AR-mediated and AR-unrelated effects. AR stabilization by Usp12 enhances transcriptional activity of AR and as a result increases cellular proliferation. We report that Usp12 acts in a pro-proliferative manner in PCa cells, which suggests that Usp12 may play a crucial role in prostate cancer development, progression, and metastasis. It remains to be established whether mutations in Usp12 are associated with PCa occurrence and progression. Detailed impact of Usp12 in PCa and its potential as a therapeutic target needs further assessment in the future.

Acknowledgments—We thank Prof. A. D'Andrea for Uaf-1 and WDR20 plasmids and Claudia A. Ryan-Munden for technical expertise.

REFERENCES

- Culig, Z. (2003) Role of the androgen receptor axis in prostate cancer. *Urology* **62**, 21–26
- Feldman, B. J., and Feldman, D. (2001) The development of androgen-independent prostate cancer. *Nat. Rev. Cancer* **1**, 34–45
- Ryan, C. J., Smith, A., Lal, P., Satagopan, J., Reuter, V., Scardino, P., Gerald, W., and Scher, H. I. (2006) Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. *Urology* **68**, 834–839
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. *Nat. Med.* **10**, 33–39
- Palazzolo, I., Burnett, B. G., Young, J. E., Brenne, P. L., La Spada, A. R., Fischbeck, K. H., Howell, B. W., and Pennuto, M. (2007) Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. *Hum. Mol. Genet.* **16**, 1593–1603
- Chymkowitch, P., Le May, N., Charneau, P., Compe, E., and Egly, J. M. (2011) The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. *EMBO J.* **30**, 468–479
- Chen, S., Kesler, C. T., Paschal, B. M., and Balk, S. P. (2009) Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. *J. Biol. Chem.* **284**, 25576–25584
- Ogryzko, V. V. (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* **87**, 953–959
- Brady, M. E., Ozanne, D. M., Gaughan, L., Waite, I., Cook, S., Neal, D. E., and Robson, C. N. (1999) Tip60 is a nuclear hormone receptor coactivator. *J. Biol. Chem.* **274**, 17599–17604
- Gaughan, L., Logan, I. R., Cook, S., Neal, D. E., and Robson, C. N. (2002) Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. *J. Biol. Chem.* **277**, 25904–25913
- Fu, M., Liu, M., Sauve, A. A., Jiao, X., Zhang, X., Wu, X., Powell, M. J., Yang, T., Gu, W., Avantaggiati, M. L., and Pestell, R. G. (2006) Hormonal control of androgen receptor function through SIRT1. *Mol. Cell. Biol.* **26**, 8122–8135
- Nishida, T., and Yasuda, H. (2002) PIAS1 and PIASx α function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. *J. Biol. Chem.* **277**, 41311–41317
- Gaughan, L., Logan, I. R., Neal, D. E., and Robson, C. N. (2005) Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. *Nucleic Acids Res.* **33**, 13–26
- Lin, H. K., Wang, L., Hu, Y. C., Altuwajri, S., and Chang, C. (2002) Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. *EMBO J.* **21**, 4037–4048
- He, B., Bai, S., Hnat, A. T., Kalman, R. I., Minges, J. T., Patterson, C., and Wilson, E. M. (2004) An androgen receptor NH₂-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (ChIP). *J. Biol. Chem.* **279**, 30643–30653
- Cardozo, C. P., Michaud, C., Ost, M. C., Fliss, A. E., Yang, E., Patterson, C., Hall, S. J., and Caplan, A. J. (2003) C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. *Arch. Biochem. Biophys.* **410**, 134–140
- Li, H., Xu, L. L., Masuda, K., Raymundo, E., McLeod, D. G., Dobi, A., and Srivastava, S. (2008) A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. *J. Biol. Chem.* **283**, 28988–28995
- Shenoy, S. K., Xiao, K., Venkataramanan, V., Snyder, P. M., Freedman, N. J., and Weissman, A. M. (2008) Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the β_2 -adrenergic receptor. *J. Biol. Chem.* **283**, 22166–22176
- Xu, K., Shimelis, H., Linn, D. E., Jiang, R., Yang, X., Sun, F., Guo, Z., Chen, H., Li, W., Chen, H., Kong, X., Melamed, J., Fang, S., Xiao, Z., Veenstra, T. D., and Qiu, Y. (2009) Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. *Cancer Cell* **15**, 270–282
- Coffey, K., and Robson, C. N. (2012) Regulation of the androgen receptor by post-translational modifications. *J. Endocrinol.* **215**, 221–237
- Dirac, A. M., and Bernards, R. (2010) The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. *Mol. Cancer Res.* **8**, 844–854
- Faus, H., Meyer, H. A., Huber, M., Bahr, I., and Haendler, B. (2005) The ubiquitin-specific protease USP10 modulates androgen receptor function. *Mol. Cell. Endocrinol.* **245**, 138–146
- Joo, H. Y., Jones, A., Yang, C., Zhai, L., Smith, A. D., 4th, Zhang, Z., Chandrasekharan, M. B., Sun, Z. W., Renfrow, M. B., Wang, Y., Chang, C., and Wang, H. (2011) Regulation of histone H2A and H2B deubiquitination and *Xenopus* development by USP12 and USP46. *J. Biol. Chem.* **286**, 7190–7201
- Moretti, J., Chastagner, P., Liang, C. C., Cohn, M. A., Israël, A., and Brou, C. (2012) The ubiquitin-specific protease 12 (USP12) is a negative regulator of notch signaling acting on notch receptor trafficking toward degradation. *J. Biol. Chem.* **287**, 29429–29441
- Cohn, M. A., Kee, Y., Haas, W., Gygi, S. P., and D'Andrea, A. D. (2009) UAF1 is a subunit of multiple deubiquitinating enzyme complexes. *J. Biol. Chem.* **284**, 5343–5351
- Kee, Y., Yang, K., Cohn, M. A., Haas, W., Gygi, S. P., and D'Andrea, A. D. (2010) WDR20 regulates activity of the USP12 x UAF1 deubiquitinating enzyme complex. *J. Biol. Chem.* **285**, 11252–11257
- Faesen, A. C., Luna-Vargas, M. P., Geurink, P. P., Clerici, M., Merckx, R., van Dijk, W. J., Hameed, D. S., El Oualid, F., Ovaa, H., and Sixma, T. K. (2011) The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. *Chem. Biol.* **18**, 1550–1561

Usp12 Is a Novel Positive Regulator of the AR

28. Kouranti, I., McLean, J. R., Feoktistova, A., Liang, P., Johnson, A. E., Roberts-Galbraith, R. H., and Gould, K. L. (2010) A global census of fission yeast deubiquitinating enzyme localization and interaction networks reveals distinct compartmentalization profiles and overlapping functions in endocytosis and polarity. *PLoS Biol.* **8**, e1000471
29. Coffey, K., Rogerson, L., Ryan-Munden, C., Alkaraif, D., Stockley, J., Heer, R., Sahadevan, K., O'Neill, D., Jones, D., Darby, S., Staller, P., Mantilla, A., Gaughan, L., and Robson, C. N. (2013) The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. *Nucleic Acids Res.* **41**, 4433–4466
30. Lu, S., Tsai, S. Y., and Tsai, M. J. (1999) Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. *Endocrinology* **140**, 5054–5059
31. Coffey, K., Blackburn, T. J., Cook, S., Golding, B. T., Griffin, R. J., Hardcastle, I. R., Hewitt, L., Huberman, K., McNeill, H. V., Newell, D. R., Roche, C., Ryan-Munden, C. A., Watson, A., and Robson, C. N. (2012) Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. *PLoS One* **7**, e45539
32. Logan, I. R., Gaughan, L., McCracken, S. R., Sapountzi, V., Leung, H. Y., and Robson, C. N. (2006) Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. *Mol. Cell. Biol.* **26**, 6502–6510
33. Logan, I. R., McNeill, H. V., Cook, S., Lu, X., Meek, D. W., Fuller-Pace, F. V., Lunec, J., and Robson, C. N. (2009) Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage. *Nucleic Acids Res.* **37**, 2962–2973
34. Deleted in proof
35. Draker, R., Sarcinella, E., and Cheung, P. (2011) USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation. *Nucleic Acids Res.* **39**, 3529–3542

Deubiquitinating Enzyme Usp12 Is a Novel Co-activator of the Androgen Receptor

Urszula L. Burska, Victoria J. Harle, Kelly Coffey, Steven Darby, Hollie Ramsey,
Daniel O'Neill, Ian R. Logan, Luke Gaughan and Craig N. Robson

J. Biol. Chem. 2013, 288:32641-32650.

doi: 10.1074/jbc.M113.485912 originally published online September 21, 2013

Access the most updated version of this article at doi: [10.1074/jbc.M113.485912](https://doi.org/10.1074/jbc.M113.485912)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 34 references, 17 of which can be accessed free at
<http://www.jbc.org/content/288/45/32641.full.html#ref-list-1>